Loading stock data…
Apogee Therapeutics (APGE)
$134.28+0.02 (+0.01%)
Market ClosedLast close Jul 24
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apogee Therapeutics, Inc. in the Healthcare sector is trading at $134.28 with a market capitalization of $6.4B. Wall Street consensus targets $130.53 (12 analysts), implying a -2.8% move over the next 12 months. The stock is currently near its 52-week high of $134.40, remaining 66.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$82.77M↓ | -$78.06M↓ | -$71.28M↑ | -$73.17M↓ | -$63.10M |
| Net Income | -$74.11M↓ | -$69.39M↓ | -$65.02M↑ | -$66.10M↓ | -$55.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indicat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.36B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.87%
Volume
Today's trading volume
465,439
Recent News
Biotech IPO Gains Crush AI Listings With Standout 55% Return
(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?
There's no need to panic.
What This Apogee Insider Move Might Mean After a 247% Stock Run
Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift.
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.
Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued?
Apogee Therapeutics (APGE) has attracted fresh attention after recent trading data showed sharp share price moves over the past month. This has prompted investors to reassess this clinical stage biotech’s risk and return profile. See our latest analysis for Apogee Therapeutics. At a latest share price of $133.57, Apogee Therapeutics has seen a 57.14% 30 day share price return and a 76.26% year to date share price return, while the 1 year total shareholder return sits at 246.31%. This...